Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Newer quinolones able to tackle many ocular surface bacteria
Stanford, CA-In vitro susceptibility test results demonstrate that the newer, 8-methoxy fluoroquinolones gatifloxacin (Zymar, Allergan) and moxifloxacin (Vigamox, Alcon) outperform older fluoroquinolones in their activity against gram-positive ocular isolates, including those with resistance to multiple other antibiotics, said Herminia Mi?o de Kaspar, PhD, senior research associate, department of ophthalmology, Stanford University, Stanford, CA.
Related Videos
Related Content
